Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Shareholder Meeting (November 2019)
15 slides from Mayne Pharma's shareholder meeting presentation, Nov 22, 2019
Slide 1: Mayne Pharma Group Limited Annual General Meeting
Mayne Pharma Group Limited For personal use only Annual General Meeting 22 November 2019
Slide 2: Disclaimer
Disclaimer For personal use only This material is not intended to be relied upon as advice to investors or potential investors. Forward looking statements ● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainti
Slide 3: Chairman's Address
For personal use only CHAIRMAN’S ADDRESS
Slide 4: US peer share price performance
US peer share price performance For personal use only Relative share price performance Share price change 120% Company 1-Year 2-Year 5-Year 100% (46%) (11%) (27%) 80% (53%) (22%) (82%) 60% (48%) (54%) (69%) 40% (83%) Na Na 20% (63%) (38%) (93%) 0% 50% (64%) (80%) Nov-18 Jan-19 Mar-19 May-19 Jul-19 S
Slide 5: FY19 overview
FY19 overview For personal use only ● Reported sales of A$525.2m, down 1% ● Reported EBITDA of A$111.6m and underlying EBITDA of A$130.9m ● Reported net loss after tax of A$(280.8)m driven by asset impairments ● Positive operating cash flow of A$106.6m ● Net debt reduced by A$18.0m in 2HFY19 with ba
Slide 6: Actively rebalancing the portfolio to specialty products led by E4/DRSP
Actively rebalancing the portfolio to specialty products led by the commercialisation of E4/DRSP oral contraceptive For personal use only FY19 revenue by type FY24F revenue by type1 (illustrative purposes only) <20% 34% 45% A$525m >60% US specialty products1 US contract services US retail generics /
Slide 7: CEO's Address
For personal use only CEO’S ADDRESS
Slide 8: Year to date trading update
Year to date trading update For personal use only Change % Change % Jul - Oct 19 Jul - Oct 18 Jan - Apr 19 versus pcp versus A$million (4 months) (4 months) (4 months) Jul - Oct 18 Jan - Apr 19 Specialty Brands 26.3 26.4 28.0 (1%) (6%) Contract Services 25.5 22.0 24.9 16% 2% Generic Products 88.6 12
Slide 9: Dermatology products TRx performance
Dermatology products TRx performance For personal use only Foam weekly prescriptions (TRx) DORYX® weekly prescriptions (TRx) 3,000 4,500 4,000 2,500 3,500 2,000 3,000 2,500 1,500 2,000 1,000 1,500 1,000 500 500 0 - FABIOR SORILUX LEXETTE DORYX 200mg generic DORYX other Source: IQVIA TRx, 8 November
Slide 10: TOLSURA establishes a new US infectious disease platform
TOLSURA® establishes a new US infectious disease platform For personal use only ● TOLSURA® listed on 6 IDN1 / hospital networks representing 11% of institutional itraconazole market volume ● US addressable market: US$300m2 - Expect to broaden the therapeutic use of TOLSURA® through further clinical
Slide 11: E4/DRSP oral contraceptive overview
E4/DRSP oral contraceptive overview For personal use only ● 20-year exclusive license and supply agreement for E4/DRSP in the US ● Novel, next generation combined hormonal contraceptive (CHC) ● Two Phase 3 studies conducted in >3,700 patients with positive results ● Expect to launch 1HCY21 subject t
Slide 12: E4 (Estetrol): a unique mode of action
E4 (Estetrol): a unique mode of action For personal use only Antagonist on the membrane receptor E4 blocks the estrogen receptor in the breast and has a neutral effect on the Agonist on the nuclear liver receptor E4 activates the nuclear estrogen receptor in bone, vagina, endometrium stability and h
Slide 13: Benefits of E4/DRSP oral contraceptive
Benefits of E4/DRSP oral contraceptive For personal use only ✓ Studied in 4,400 women during Phase 2 and Phase 3 with low adverse events Phase 3 studies showed E4/DRSP was highly efficacious including in high BMI ✓ women and had neutral effect on lipids or glucose metabolism ✓ Minimal impact on hepa
Slide 14: Combined hormonal contraceptive market
Combined hormonal contraceptive market For personal use only CHC market IQVIA sales of key CHC brands US$970m US$830m 7% Combined oral contraceptive 24% US$4.0b Vaginal ring US$290m 69% US$170m Patch Ring Pill Patch Pill % share of CHC 4.9% 4.4% 1.9% 0.7% market by units US patient population of 10
Slide 15: Outlook
Outlook For personal use only ● Generic Products performance will depend on many factors including timing of FDA approvals, competitor launches and withdrawals on key products ● Specialty Brands expected to benefit from product launches of TOLSURA® and LEXETTE®, and from E4/DRSP in FY22 ● Contract S
Mayne Pharma Group — Shareholder Meeting (November 2019) on 6ix